• search

Suven Life Sciences to file IND on Alzheimer disease

Written by: Staff

Hyderabad, Apr 29 (UNI) Suven Life Sciences, a Hyderabad-based Life Sciences company, today said that it is in final phases of filing its first Investigational New Drug (IND) application with USFDA during this year in the therapeutic area of CNS focusing on Alzheimer's disease.

During the year, Suven spent 20 per cent of its revenue on R&D and has so far filed 32 product patents, a company release said here.

With 100 per cent growth in the net profit for the financial year 2005-06, the total income of the company stood at Rs. 8293.90 lacs, registering a growth of 36 per cent, against the total income of Rs 6077.93 lacs of the previous year. The net profit is at Rs 763.91 lacs at 100 per cent, up against the net of Rs 379.72 lacs for the previous year.

''There is a significant growth in exports by 95 per cent and domestic sales by 51 per cent. Quarter on Quarter basis the growth in total income stood at 40 per cent and growth in the net profit stood at 25 per cent, the release added.


For Daily Alerts
Get Instant News Updates
Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more